Precision medicine is on the rise and Paul Mampilly seems to have discovered the company that is making headways in this field. He believes that Myriad Genetic is a rising global leader in the healthcare sector. The experts believe that precision medicine is a defining method in dealing with disease and it will cause a revolution in disease management and treatment.
This revolutionary method involves tailoring drugs and intervention methods based on the DNA of an individual. Physicians, doctors and healthcare givers need to study and understand the genetic makeup of an individual and determine the most appropriate solution based on what they find out. Death sentences from doctors will be a thing of the past if this is anything to go by.
Many other companies have been involved in customized treatment, testing genetic material and developing the technology to facilitate precision medicine. The $1.5 billion company, established in the early 1990s, is located in Utah in the outskirts of Salt Lake City. Its chief executive has worked in the biotechnology industry for more than two decades. According to Paul Mampilly, he is working on poaching the best scientific brains across the world to actualize their dream.
The mid-Western company is more concerned about the various forms of cancer that continue to claim the lives of many Americans. They conduct DNA sequencing to determine what an individual is predisposed to and what treatment regimen will yield the best results. This technique is far much better compared to the radiotherapy and chemotherapy treatments that have been prescribed to patients in a general way. Follow Paul on twitter.com.
Cancer testing is the main revenue driver for the company which also offers non-cancer testing programs. Colon and breast cancer are the top of their hereditary cancer screening services. Their testing services provide an option for prevention of cancer spread as they allow it to be detected in good time. They also go a long way in cutting down the risk of contracting the disease. Paul Mampilly believes that these services have impressed insurance companies which have not shied away from putting their weight behind Myriad Genetics.
Paul Mampilly first recommended the company’s stock when they sold at $24. Its monopoly in the cancer screening market has seen Myriad rise to a $2.2 billion stock. Despite the slight decline in their share earnings in 2017, analysts expect them to gain rises that will see them hit their former heights. Time will tell whether they will weather the storm of their competitors and keep their place at the top of precision medicine companies. Read more about Paul Mampilly at Talk Markets.